Loading
A phase 3 trial of SYS6010, tislelizumab, toripalimab, durvalumab and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT07672223 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 570 participants, started 2026-06-25 and due to reach its primary completion in 2029-09-30. Interventions recorded: SYS6010; Enlonstobart; Tislelizumab; Toripalimab ±+platinum-based doublet chemotherapy; Durvalumab; Pembrolizumab; Nivolumab. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS) assessed by the independent review committee (IRC). Lung eligibility wording from the registry: "Histologically confirmed squamous or non-squamous NSCLC". No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares SYS6010, CSPC Pharmaceutical Group, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares SYS6010, CSPC Pharmaceutical Group, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Tislelizumab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares SYS6010, CSPC Pharmaceutical Group, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Toripalimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.